Spiropyrrolizine derivatives as multitarget antidiabetic agents in obese type 2 diabetes: integrated in silico, in vitro, and in vivo evaluation of DPP-4 inhibition and hepatic enzyme modulation.

Key Points

• Evaluate the efficacy of spiropyrrolizine derivatives as multitarget antidiabetic agents for managing obese type 2 diabetes.
• Integrated in silico, in vitro, and in vivo evaluations conducted
• Assessment of DPP-4 inhibition
• Analysis of hepatic enzyme modulation
• Behavioral and biochemical tests in relevant models
• Spiropyrrolizine 4d shows significant DPP-4 inhibition
• Demonstrated positive modulation of hepatic enzymes
• Identified as a promising candidate for managing OB-T2D